Cardio-oncology is a new multidisciplinary field that seeks to address the cardiac problems occurring during or post cancer treatment. Several international guidelines for monitoring cardio-oncology side effects have been developed; however, there is no literature available for the pediatric population. To address this gap, Delphi experts from Australia and New Zealand have provided the first-of-its-kind recommendations for performing risk assessment, screening, and follow-up specific to pediatric oncology patients.
Read on to get more insights on the further domains of surveillance and toxicity management for patients receiving VEGF inhibitors, mTOR inhibitors, BCR-Abl kinase inhibitors, and proteasomal inhibitors. Any patient with ongoing documented toxicities should be considered for discussion at the cardio-oncology multidisciplinary team meeting for all the inhibitors mentioned…
